ID   LIPL_RAT                Reviewed;         474 AA.
AC   Q06000;
DT   01-FEB-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1994, sequence version 1.
DT   29-MAY-2024, entry version 181.
DE   RecName: Full=Lipoprotein lipase;
DE            Short=LPL;
DE            EC=3.1.1.34 {ECO:0000250|UniProtKB:P11151};
DE   AltName: Full=Phospholipase A1;
DE            EC=3.1.1.32 {ECO:0000250|UniProtKB:P06858};
DE   Flags: Precursor;
GN   Name=Lpl;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Sprague-Dawley; TISSUE=Testis;
RX   PubMed=1339374; DOI=10.1016/0378-1119(92)90127-b;
RA   Brault D., Noe L., Etienne J., Hamelin J., Raisonnier A., Souli A.,
RA   Chuat J.-C., Dugail I., Quignard-Boulange A., Lavau M., Galibert F.;
RT   "Sequence of rat lipoprotein lipase-encoding cDNA.";
RL   Gene 121:237-246(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 336-474, AND INDUCTION.
RC   TISSUE=Heart;
RX   PubMed=2233752; DOI=10.1210/mend-4-9-1416;
RA   Raynolds M.V., Awald P.D., Gordon D.F., Gutierrez-Hartmann A., Rule D.C.,
RA   Wood W.M., Eckel R.H.;
RT   "Lipoprotein lipase gene expression in rat adipocytes is regulated by
RT   isoproterenol and insulin through different mechanisms.";
RL   Mol. Endocrinol. 4:1416-1422(1990).
RN   [4]
RP   NITRATION AT TYR-121; TYR-191 AND TYR-343, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=19715756; DOI=10.1016/j.freeradbiomed.2009.08.020;
RA   Casanovas A., Carrascal M., Abian J., Lopez-Tejero M.D., Llobera M.;
RT   "Lipoprotein lipase is nitrated in vivo after lipopolysaccharide
RT   challenge.";
RL   Free Radic. Biol. Med. 47:1553-1560(2009).
RN   [5]
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND GLYCOSYLATION.
RX   PubMed=19527804; DOI=10.1016/j.jprot.2009.06.002;
RA   Casanovas A., Carrascal M., Abian J., Lopez-Tejero M.D., Llobera M.;
RT   "Discovery of lipoprotein lipase pI isoforms and contributions to their
RT   characterization.";
RL   J. Proteomics 72:1031-1039(2009).
CC   -!- FUNCTION: Key enzyme in triglyceride metabolism (By similarity).
CC       Catalyzes the hydrolysis of triglycerides from circulating chylomicrons
CC       and very low density lipoproteins (VLDL), and thereby plays an
CC       important role in lipid clearance from the blood stream, lipid
CC       utilization and storage (By similarity). Although it has both
CC       phospholipase and triglyceride lipase activities it is primarily a
CC       triglyceride lipase with low but detectable phospholipase activity (By
CC       similarity). Mediates margination of triglyceride-rich lipoprotein
CC       particles in capillaries (By similarity). Recruited to its site of
CC       action on the luminal surface of vascular endothelium by binding to
CC       GPIHBP1 and cell surface heparan sulfate proteoglycans (By similarity).
CC       {ECO:0000250|UniProtKB:P06858}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a triacylglycerol + H2O = a diacylglycerol + a fatty acid +
CC         H(+); Xref=Rhea:RHEA:12044, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:17855, ChEBI:CHEBI:18035, ChEBI:CHEBI:28868; EC=3.1.1.34;
CC         Evidence={ECO:0000250|UniProtKB:P11151};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1,2-diacyl-sn-glycero-3-phosphocholine + H2O = a 2-acyl-sn-
CC         glycero-3-phosphocholine + a fatty acid + H(+); Xref=Rhea:RHEA:18689,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:28868,
CC         ChEBI:CHEBI:57643, ChEBI:CHEBI:57875; EC=3.1.1.32;
CC         Evidence={ECO:0000250|UniProtKB:P06858};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1,2,3-tri-(9Z-octadecenoyl)-glycerol + H2O = (9Z)-
CC         octadecenoate + di-(9Z)-octadecenoylglycerol + H(+);
CC         Xref=Rhea:RHEA:38575, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:30823, ChEBI:CHEBI:53753, ChEBI:CHEBI:75945;
CC         Evidence={ECO:0000250|UniProtKB:P06858};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:38576;
CC         Evidence={ECO:0000250|UniProtKB:P06858};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine + H2O =
CC         (9Z)-octadecenoate + (9Z-octadecenoyl)-sn-glycero-3-phosphocholine +
CC         H(+); Xref=Rhea:RHEA:38699, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:30823, ChEBI:CHEBI:74669, ChEBI:CHEBI:76083;
CC         Evidence={ECO:0000250|UniProtKB:P06858};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:38700;
CC         Evidence={ECO:0000250|UniProtKB:P06858};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1,2,3-tributanoylglycerol + H2O = butanoate +
CC         dibutanoylglycerol + H(+); Xref=Rhea:RHEA:40475, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:17968, ChEBI:CHEBI:35020,
CC         ChEBI:CHEBI:76478; Evidence={ECO:0000250|UniProtKB:P06858};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40476;
CC         Evidence={ECO:0000250|UniProtKB:P06858};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1,2-dihexadecanoyl-sn-glycero-3-phosphocholine + H2O = H(+) +
CC         hexadecanoate + hexadecanoyl-sn-glycero-3-phosphocholine;
CC         Xref=Rhea:RHEA:41384, ChEBI:CHEBI:7896, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:64563, ChEBI:CHEBI:72999;
CC         Evidence={ECO:0000250|UniProtKB:P06858};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41385;
CC         Evidence={ECO:0000250|UniProtKB:P06858};
CC   -!- ACTIVITY REGULATION: The apolipoprotein APOC2 acts as a coactivator of
CC       LPL activity (By similarity). Ca(2+) binding promotes protein stability
CC       and formation of the active homodimer. Interaction with GPIHBP1
CC       protects LPL against inactivation by ANGPTL4 (By similarity).
CC       {ECO:0000250|UniProtKB:P06858, ECO:0000250|UniProtKB:P11151}.
CC   -!- SUBUNIT: Homodimer. Interacts with GPIHBP1 with 1:1 stoichiometry (By
CC       similarity). Interacts with APOC2; the interaction activates LPL
CC       activity in the presence of lipids (By similarity). Interaction with
CC       heparan sulfate proteoglycans is required to protect LPL against loss
CC       of activity. Associates with lipoprotein particles in blood plasma.
CC       Interacts with LMF1 and SEL1L; interaction with SEL1L is required to
CC       prevent aggregation of newly synthesized LPL in the endoplasmic
CC       reticulum (ER), and for normal export of LPL from the ER to the
CC       extracellular space (By similarity). Interacts with SORL1; SORL1 acts
CC       as a sorting receptor, promoting LPL localization to endosomes and
CC       later to lysosomes, leading to degradation of newly synthesized LPL (By
CC       similarity). {ECO:0000250|UniProtKB:P06858,
CC       ECO:0000250|UniProtKB:P11151}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250|UniProtKB:P11151};
CC       Peripheral membrane protein {ECO:0000250|UniProtKB:P11151};
CC       Extracellular side {ECO:0000250|UniProtKB:P11151}. Secreted
CC       {ECO:0000250|UniProtKB:P11151}. Secreted, extracellular space,
CC       extracellular matrix {ECO:0000250|UniProtKB:P11151}. Note=Newly
CC       synthesized LPL binds to cell surface heparan proteoglycans and is then
CC       released by heparanase. Subsequently, it becomes attached to heparan
CC       proteoglycan on endothelial cells. Locates to the plasma membrane of
CC       microvilli of hepatocytes with triglyceride-rich lipoproteins (TRL).
CC       Some of the bound LPL is then internalized and located inside non-
CC       coated endocytic vesicles. {ECO:0000250|UniProtKB:P11151}.
CC   -!- INDUCTION: Induced by insulin. Inhibited by isoproterenol.
CC       {ECO:0000269|PubMed:2233752}.
CC   -!- PTM: Tyrosine nitration after lipopolysaccharide (LPS) challenge down-
CC       regulates the lipase activity. {ECO:0000269|PubMed:19715756}.
CC   -!- SIMILARITY: Belongs to the AB hydrolase superfamily. Lipase family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L03294; AAA41534.1; -; mRNA.
DR   EMBL; BC081836; AAH81836.1; -; mRNA.
DR   PIR; JH0790; JH0790.
DR   RefSeq; NP_036730.1; NM_012598.2.
DR   AlphaFoldDB; Q06000; -.
DR   SMR; Q06000; -.
DR   STRING; 10116.ENSRNOP00000016543; -.
DR   BindingDB; Q06000; -.
DR   ChEMBL; CHEMBL5906; -.
DR   ESTHER; ratno-lipli; Lipoprotein_Lipase.
DR   GlyCosmos; Q06000; 2 sites, No reported glycans.
DR   GlyGen; Q06000; 2 sites.
DR   PhosphoSitePlus; Q06000; -.
DR   SwissPalm; Q06000; -.
DR   jPOST; Q06000; -.
DR   PaxDb; 10116-ENSRNOP00000016543; -.
DR   ABCD; Q06000; 1 sequenced antibody.
DR   Ensembl; ENSRNOT00055006035; ENSRNOP00055004558; ENSRNOG00055003827.
DR   GeneID; 24539; -.
DR   KEGG; rno:24539; -.
DR   UCSC; RGD:3017; rat.
DR   AGR; RGD:3017; -.
DR   CTD; 4023; -.
DR   RGD; 3017; Lpl.
DR   VEuPathDB; HostDB:ENSRNOG00000012181; -.
DR   eggNOG; ENOG502QQ7P; Eukaryota.
DR   HOGENOM; CLU_027171_1_0_1; -.
DR   InParanoid; Q06000; -.
DR   OrthoDB; 3428256at2759; -.
DR   PhylomeDB; Q06000; -.
DR   TreeFam; TF324997; -.
DR   BRENDA; 3.1.1.34; 5301.
DR   Reactome; R-RNO-8963889; Assembly of active LPL and LIPC lipase complexes.
DR   Reactome; R-RNO-8963901; Chylomicron remodeling.
DR   Reactome; R-RNO-975634; Retinoid metabolism and transport.
DR   PRO; PR:Q06000; -.
DR   Proteomes; UP000002494; Chromosome 16.
DR   Bgee; ENSRNOG00000012181; Expressed in heart and 20 other cell types or tissues.
DR   GO; GO:1902494; C:catalytic complex; ISO:RGD.
DR   GO; GO:0009986; C:cell surface; ISO:RGD.
DR   GO; GO:0042627; C:chylomicron; IEA:UniProtKB-KW.
DR   GO; GO:0005615; C:extracellular space; IDA:RGD.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0034361; C:very-low-density lipoprotein particle; IEA:UniProtKB-KW.
DR   GO; GO:0052740; F:1-acyl-2-lysophosphatidylserine acylhydrolase activity; IEA:UniProtKB-EC.
DR   GO; GO:0034185; F:apolipoprotein binding; ISO:RGD.
DR   GO; GO:0005509; F:calcium ion binding; ISO:RGD.
DR   GO; GO:0043395; F:heparan sulfate proteoglycan binding; ISS:UniProtKB.
DR   GO; GO:0008201; F:heparin binding; ISS:UniProtKB.
DR   GO; GO:0004465; F:lipoprotein lipase activity; IDA:CACAO.
DR   GO; GO:0071813; F:lipoprotein particle binding; ISS:UniProtKB.
DR   GO; GO:0052739; F:phosphatidylserine 1-acylhydrolase activity; IEA:UniProtKB-EC.
DR   GO; GO:0008970; F:phospholipase A1 activity; ISS:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; ISO:RGD.
DR   GO; GO:0005102; F:signaling receptor binding; ISO:RGD.
DR   GO; GO:0017129; F:triglyceride binding; IDA:RGD.
DR   GO; GO:0004806; F:triglyceride lipase activity; ISO:RGD.
DR   GO; GO:0071398; P:cellular response to fatty acid; ISO:RGD.
DR   GO; GO:0031670; P:cellular response to nutrient; ISO:RGD.
DR   GO; GO:0042632; P:cholesterol homeostasis; ISO:RGD.
DR   GO; GO:0034371; P:chylomicron remodeling; ISS:UniProtKB.
DR   GO; GO:0006633; P:fatty acid biosynthetic process; ISO:RGD.
DR   GO; GO:0006631; P:fatty acid metabolic process; ISS:UniProtKB.
DR   GO; GO:0034375; P:high-density lipoprotein particle remodeling; IBA:GO_Central.
DR   GO; GO:0016042; P:lipid catabolic process; IDA:RGD.
DR   GO; GO:0055096; P:low-density lipoprotein particle mediated signaling; ISO:RGD.
DR   GO; GO:1900077; P:negative regulation of cellular response to insulin stimulus; IMP:RGD.
DR   GO; GO:1904179; P:positive regulation of adipose tissue development; ISO:RGD.
DR   GO; GO:2000343; P:positive regulation of chemokine (C-X-C motif) ligand 2 production; ISO:RGD.
DR   GO; GO:0032722; P:positive regulation of chemokine production; ISO:RGD.
DR   GO; GO:0010886; P:positive regulation of cholesterol storage; ISO:RGD.
DR   GO; GO:0045600; P:positive regulation of fat cell differentiation; ISO:RGD.
DR   GO; GO:0050729; P:positive regulation of inflammatory response; ISO:RGD.
DR   GO; GO:0032731; P:positive regulation of interleukin-1 beta production; ISO:RGD.
DR   GO; GO:0032755; P:positive regulation of interleukin-6 production; ISO:RGD.
DR   GO; GO:0010744; P:positive regulation of macrophage derived foam cell differentiation; ISO:RGD.
DR   GO; GO:0010890; P:positive regulation of sequestering of triglyceride; ISO:RGD.
DR   GO; GO:0032760; P:positive regulation of tumor necrosis factor production; ISO:RGD.
DR   GO; GO:0009617; P:response to bacterium; ISO:RGD.
DR   GO; GO:0009410; P:response to xenobiotic stimulus; IEP:RGD.
DR   GO; GO:0019432; P:triglyceride biosynthetic process; IMP:RGD.
DR   GO; GO:0019433; P:triglyceride catabolic process; ISS:UniProtKB.
DR   GO; GO:0070328; P:triglyceride homeostasis; ISO:RGD.
DR   GO; GO:0034372; P:very-low-density lipoprotein particle remodeling; ISO:RGD.
DR   CDD; cd00707; Pancreat_lipase_like; 1.
DR   CDD; cd01758; PLAT_LPL; 1.
DR   Gene3D; 3.40.50.1820; alpha/beta hydrolase; 1.
DR   Gene3D; 2.60.60.20; PLAT/LH2 domain; 1.
DR   InterPro; IPR029058; AB_hydrolase.
DR   InterPro; IPR013818; Lipase.
DR   InterPro; IPR016272; Lipase_LIPH.
DR   InterPro; IPR033906; Lipase_N.
DR   InterPro; IPR002330; Lipo_Lipase.
DR   InterPro; IPR001024; PLAT/LH2_dom.
DR   InterPro; IPR036392; PLAT/LH2_dom_sf.
DR   InterPro; IPR000734; TAG_lipase.
DR   NCBIfam; TIGR03230; lipo_lipase; 1.
DR   PANTHER; PTHR11610; LIPASE; 1.
DR   PANTHER; PTHR11610:SF3; LIPOPROTEIN LIPASE; 1.
DR   Pfam; PF00151; Lipase; 1.
DR   Pfam; PF01477; PLAT; 1.
DR   PIRSF; PIRSF000865; Lipoprotein_lipase_LIPH; 1.
DR   PRINTS; PR00822; LIPOLIPASE.
DR   PRINTS; PR00821; TAGLIPASE.
DR   SMART; SM00308; LH2; 1.
DR   SUPFAM; SSF53474; alpha/beta-Hydrolases; 1.
DR   SUPFAM; SSF49723; Lipase/lipooxygenase domain (PLAT/LH2 domain); 1.
DR   PROSITE; PS00120; LIPASE_SER; 1.
DR   PROSITE; PS50095; PLAT; 1.
PE   1: Evidence at protein level;
KW   Calcium; Cell membrane; Chylomicron; Disulfide bond; Extracellular matrix;
KW   Glycoprotein; Heparin-binding; Hydrolase; Lipid degradation;
KW   Lipid metabolism; Membrane; Metal-binding; Nitration; Reference proteome;
KW   Secreted; Signal; VLDL.
FT   SIGNAL          1..27
FT                   /evidence="ECO:0000250"
FT   CHAIN           28..474
FT                   /note="Lipoprotein lipase"
FT                   /id="PRO_0000017779"
FT   DOMAIN          341..464
FT                   /note="PLAT"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00152"
FT   REGION          32..53
FT                   /note="Interaction with GPIHBP1"
FT                   /evidence="ECO:0000250|UniProtKB:P06858"
FT   REGION          243..266
FT                   /note="Essential for determining substrate specificity"
FT                   /evidence="ECO:0000250|UniProtKB:P06858"
FT   REGION          417..421
FT                   /note="Important for interaction with lipoprotein
FT                   particles"
FT                   /evidence="ECO:0000250|UniProtKB:P06858"
FT   REGION          430..434
FT                   /note="Important for heparin binding"
FT                   /evidence="ECO:0000250|UniProtKB:P06858"
FT   REGION          443..467
FT                   /note="Interaction with GPIHBP1"
FT                   /evidence="ECO:0000250|UniProtKB:P06858"
FT   ACT_SITE        159
FT                   /note="Nucleophile"
FT                   /evidence="ECO:0000250|UniProtKB:P06858"
FT   ACT_SITE        183
FT                   /note="Charge relay system"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU10037"
FT   ACT_SITE        268
FT                   /note="Charge relay system"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU10037"
FT   BINDING         194
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000250|UniProtKB:P06858"
FT   BINDING         197
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000250|UniProtKB:P06858"
FT   BINDING         199
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000250|UniProtKB:P06858"
FT   BINDING         202
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000250|UniProtKB:P06858"
FT   MOD_RES         121
FT                   /note="3'-nitrotyrosine"
FT                   /evidence="ECO:0000269|PubMed:19715756"
FT   MOD_RES         191
FT                   /note="3'-nitrotyrosine"
FT                   /evidence="ECO:0000269|PubMed:19715756"
FT   MOD_RES         343
FT                   /note="3'-nitrotyrosine"
FT                   /evidence="ECO:0000269|PubMed:19715756"
FT   CARBOHYD        70
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        386
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        54..67
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00152"
FT   DISULFID        243..266
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00152"
FT   DISULFID        291..310
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00152"
FT   DISULFID        302..305
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00152"
FT   DISULFID        445..465
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00152"
FT   CONFLICT        336
FT                   /note="M -> V (in Ref. 3; no nucleotide entry)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   474 AA;  53082 MW;  F4F6F4BCCA4F1626 CRC64;
     MESKALLLVA LGVWLQSLTA FRGGVAAADG GRDFSDIESK FALRTPEDTA EDTCHLIPGL
     ADSVSNCHFN HSSKTFVVIH GWTVTGMYES WVPKLVAALY KREPDSNVIV VDWLYRAQQH
     YPVSAGYTKL VGNDVARFIN WLEEEFNYPL DNVHLLGYSL GAHAAGVAGS LTNKKVNRIT
     GLDPAGPNFE YAEAPSRLSP DDADFVDVLH TFTRGSPGRS IGIQKPVGHV DIYPNGGTFQ
     PGCNIGEAIR VIAEKGLGDV DQLVKCSHER SIHLFIDSLL NEENPSKAYR CNSKEAFEKG
     LCLSCRKNRC NNVGYEINKV RAKRSSKMYL KTRSQMPYKV FHYQVKIHFS GTENDKQNNQ
     AFEISLYGTV AESENIPFTL PEVATNKTYS FLIYTEVDIG ELLMMKLKWK NDSYFRWSDW
     WSSPSFVIEK IRVKAGETQK KVIFCAREKV SHLQKGKDAA VFVKCHDKSL KKSG
//
